Safely use of omalizumab during SARS-CoV-2 infection in patients with chronic spontaneous urticaria.

Özdemir, Öner; Dikici, Ümmügülsüm

Özdemir, Öner; Dikici, Ümmügülsüm.

Affiliation

Özdemir Ö; Division of Allergy and Immunology, Department of Pediatrics, Faculty of Medicine, Research and Training Hospital of Sakarya University, Sakarya University, Sakarya, Turkey.
Dikici Ü; Division of Allergy and Immunology, Department of Pediatrics, Faculty of Medicine, Research and Training Hospital of Sakarya University, Sakarya University, Sakarya, Turkey.

J Cosmet Dermatol ; 22(1): 26-27, 2023 01.

Article in En | MEDLINE | ID: mdl-36448319

Subject(s)

Anti-Allergic Agents; COVID-19; Chronic Urticaria; Humans; Omalizumab/therapeutic use; SARS-CoV-2; Chronic Urticaria/drug therapy; Anti-Allergic Agents/therapeutic use; Chronic Disease; Treatment Outcome

Key words

COVID-19; SARS-CoV-2; chronic spontaneous urticaria; omalizumab

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Anti-Allergic Agents / Chronic Urticaria / COVID-19 Limits: Humans Language: En Journal: J Cosmet Dermatol Journal subject: DERMATOLOGIA Year: 2023 Document type: Article Affiliation country: Turkey Country of publication: United kingdom

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google